Genenta Science S.p.A. (GNTA), Tuesday announced long-term follow-up data from its TEM-GBM study of Temferon in glioblastoma multiforme patients.
The study enrolled a total of 38 patients, with 25 patients receiving Temferon. Of this, two patients survived three years from the time of the first surgery.
The company noted that a 29 percent two-year survival rate for unmethylated MGMT patients, with median overall survival at 17 months. This is in comparison to patients receiving standard of care have shown a two-year survival rate of approximately 14 percent and a median overall survival of 13 to 15 months.
Also, the company has initiated the TEM-GU Phase 1 study, which intends to enroll 12 patients with genitourinary tumors, aiming to demonstrate the safety and tolerability of Temferon in patients with Metastatic Renal Cell Carcinoma by year-end.
In the pre-market hours, GNTA is moving up 11.99 percent, to $3.41 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.